Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VTB to receive ₽112 billion in dividends from Otkritie

12/29/23 VTBR

Nauka reported for 9 months of 2023 by RAS

12/29/23 NAUK

SPB Exchange invites shareholders to the EGM

12/29/23 SPBE

SPB Exchange resumes trading

12/29/23 SPBE

Board of Directors of Samolet approved the buyback for next year

12/29/23 SMLT

Gazprom built the fourth line of the Amur Gas Processing Plant

12/29/23 GAZP

SPB Exchange reported suspension of trading due to technical failure

12/29/23 SPBE

VTB may conduct a reverse split of shares

12/29/23 VTBR

Sovcombank wants to start issuing structured bonds

12/28/23 SVCB

Mikron doubles revenue and turns a profit

12/28/23 AFKS